Manchester Capital Management’s Adial Pharmaceuticals ADIL Stock Holding History

Manchester Capital Management’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.44K	Sell	1,923 -1	-0.1%	-$4	﹤0.01%	931
2025 Q4	$10.6K	Hold	1,924	–	–	﹤0.01%	773
2025 Q3	$17K	Hold	1,924	–	–	﹤0.01%	772
2025 Q2	$14.5K	Hold	1,924	–	–	﹤0.01%	780
2025 Q1	$30.5K	Hold	1,924	–	–	﹤0.01%	638
2024 Q4	$48.6K	Hold	1,924	–	–	0.01%	542
2024 Q3	$48K	Hold	1,924	–	–	0.01%	546
2024 Q2	$55.3K	Hold	1,924	–	–	0.01%	479
2024 Q1	$64K	Hold	1,924	–	–	0.01%	445
2023 Q4	$89.5K	Hold	1,924	–	–	0.01%	368
2023 Q3	$134K	Hold	1,924	–	–	0.02%	315
2023 Q2	$250K	Hold	1,924	–	–	0.03%	248
2023 Q1	$421K	Buy	+1,924	New	+$466K	0.06%	201

Other funds holding ADIL

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Manchester Capital Management's ADIL Position: Q1 2026 in Review

Manchester Capital Management reduced its Adial Pharmaceuticals (ADIL) stake by 0.05% in Q1 2026, selling an estimated $4 and leaving 1,923 shares worth $3.44K. The position accounts for ﹤0.01% of the portfolio, ranked #931.

Manchester Capital Management first reported a position in ADIL in Q1 2023 and has held it in 13 quarters since. The position peaked at $421K in Q1 2023. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

Manchester Capital Management held 1,923 shares of Adial Pharmaceuticals worth $3.44K as of Q1 2026.
Manchester Capital Management sold 1 Adial Pharmaceuticals share in Q1 2026, an estimated $4.
Adial Pharmaceuticals made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #931 holding.
Manchester Capital Management first reported a position in Adial Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Manchester Capital Management's Adial Pharmaceuticals position peaked at $421K in Q1 2023.
14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.